Multiple outlets report on a UK–US pharmaceutical pricing arrangement agreed in December and the impact it could have on NHS spending and patient outcomes. A new analysis in England, cited by The Guardian and discussed by Al Jazeera, suggests that the deal would require the NHS to divert significant funds from other services to pay more for new medicines. One figure cited is £45bn redirected from essential services to fund medicines, and the analysis projects potential excess deaths of more than 200,000, including a headline estimate of 229,000 by 2036. The outlets describe critics as arguing the agreement effectively prioritises higher medicine prices over wider NHS care capacity. The Guardian also reports that ministers defend the deal as supporting British drug exports by helping them avoid US tariffs and improving patient access to potentially life-extending treatments. In contrast, a letter published by The Guardian disputes the excess-deaths modelling as alarmist and argues it relies on incomplete data. Overall, the sources present competing views: the analysis projects large harm if budgets are constrained, while the government and some commentators argue it expands access to new therapies and is based on contested assumptions.